Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer

PURPOSE: The TAXYNERGY trial (ClinicalTrials.gov identifier: NCT01718353) evaluated clinical benefit from early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity or resistance to taxanes in men with chemotherapy-naïve, metastatic, castration-resistant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Antonarakis, Emmanuel S., Tagawa, Scott T., Galletti, Giuseppe, Worroll, Daniel, Ballman, Karla, Vanhuyse, Marie, Sonpavde, Guru, North, Scott, Albany, Costantine, Tsao, Che-Kai, Stewart, John, Zaher, Atef, Szatrowski, Ted, Zhou, Wei, Gjyrezi, Ada, Tasaki, Shinsuke, Portella, Luigi, Bai, Yang, Lannin, Timothy B., Suri, Shalu, Gruber, Conor N., Pratt, Erica D., Kirby, Brian J., Eisenberger, Mario A., Nanus, David M., Saad, Fred, Giannakakou, Paraskevi
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2017
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791829/
https://ncbi.nlm.nih.gov/pubmed/28632486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.72.4138
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars